Osimertinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Osimertinib comprises 261 peer-reviewed publications across 15 journals, 10 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis, Lung Neoplasms, and Neoplasm Metastasis. Most recent publication: Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial., Clin Lung Cancer, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, et al. · N Engl J Med · 2018
    PubMed: PMID 29151359 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  2. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, et al. · Lancet Oncol · 2015
    PubMed: PMID 25175099 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  3. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Saito H, Fukuhara T, Furuya N, et al. · Lancet Oncol · 2020
    PubMed: PMID 30975627 · NCT04029350 (ALTN-03) · Carcinoma, Non-Small-Cell Lung
  4. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R, Dafni U, Felip E, et al. · Lancet Respir Med · 2018
    PubMed: PMID 28408243 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  5. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    Ramalingam SS, Vansteenkiste J, Planchard D, et al. · N Engl J Med · 2020
    PubMed: PMID 31751012 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  6. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS, Wu Y-L, Ahn M-J, et al. · N Engl J Med · 2017
    PubMed: PMID 27959700 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  7. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA, Yang JC, Kim DW, et al. · N Engl J Med · 2015
    PubMed: PMID 25923549 · NCT07361705 · Meningeal Carcinomatosis
  8. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G, Tsai CM, Shepherd FA, et al. · Lancet Oncol · 2017
    PubMed: PMID 27751847 · NCT07361705 · Meningeal Carcinomatosis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02151981
AURA3
—Progression Free Survival (PFS) by Investigator Assessment
RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).
Chemotherapy4.4 Months
Osimertinib 80mg10.1 Months
NCT02411448
RELAY
Carcinoma, Non-Small-Cell LungNumber of Participants With Treatment-Emergent Adverse Events
Cycle 1 Day 1 through End of Study (Up To 3 Years)
Part A: Ramucirumab + Erlotinib14 Participants
Part B: Placebo + Erlotinib225 Participants
Part B: Ramucirumab + Erlotinib221 Participants
NCT02411448
RELAY
Carcinoma, Non-Small-Cell LungPart B: Progression Free Survival (PFS)
Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Part B: Placebo+ Erlotinib12.4 Months
Part B: Ramucirumab+ Erlotinib19.4 Months
NCT03521154
LAURA
Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS) by Blinded Independent Central Review (BICR)
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Osimertinib39.13 Months
Placebo5.55 Months
NCT04035486
FLAURA2
Carcinoma, Non-Small-Cell LungAdverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only)
From first dose date to 28 days following last dose, up to 45 months
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed2 Participants
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed0 Participants
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed1 Participants
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed9 Participants
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed3 Participants
Safety Run-In: AZD9291 + Carboplatin + Pemetrexed0 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed2 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed0 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed8 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed4 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed0 Participants
Safety Run-In: AZD9291 + Cisplatin + Pemetrexed1 Participants
NCT04035486
FLAURA2
Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS) (Randomized Component)
Up to approximately 33 months after the first patient is randomized (maximum follow up of 33.3 months)
Randomized: AZD929116.7 Months
Randomized: AZD9291 + Chemo25.5 Months
NCT04035486
FLAURA2
Carcinoma, Non-Small-Cell LungSensitivity Analysis for Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Randomized Component)
Up to approximately 33 months after the first patient is randomized (maximum follow up of 33.2 months).
Randomized: AZD929119.9 Months
Randomized: AZD9291 + Chemo29.4 Months
NCT04487080
MARIPOSA
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
From randomization to either disease progression or death whichever occurs first (up to 32.8 months)
Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib16.59 Months
Experimental: Arm A (Open-label): Amivantamab + Lazertinib23.72 Months
Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib18.46 Months
NCT04765059
COMPEL
Carcinoma, Non-Small-Cell LungProgression Free Survival (PFS)
From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month)
Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin8.4 Months
Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin4.4 Months
NCT04816214
GEOMETRY-E
Carcinoma, Non-Small-Cell LungRun-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)
Up to 21 Days
Run-in Part: Capmatinib + Osimertinib0 Participants

Publications by year

1984–2026: 261 publications.

1984
1
1987
1
1990
1
1995
1
1997
2
2001
1
2002
2
2003
1
2005
3
2006
4
2007
2
2008
4
2009
4
2010
5
2011
8
2012
7
2013
3
2014
8
2015
12
2016
11
2017
8
2018
15
2019
21
2020
23
2021
20
2022
25
2023
16
2024
20
2025
23
2026
9

Publications by indication

Carcinoma, Non-Small-Cell Lung (189)

  • Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
    Clin Lung Cancer · 2026 · PMID 41308232 · NCT03778229
  • Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Ann Oncol · 2026 · PMID 41780641 · NCT03944772
  • Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
    JTO Clin Res Rep · 2026 · PMID 40458541 · NCT02411448
  • Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lancet · 2026 · PMID 41544643 · NCT05015608
  • A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
    Future Oncol · 2026 · PMID 42037107 · NCT03521154

Meningeal Carcinomatosis (20)

  • Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study.
    Ther Adv Med Oncol · 2022 · PMID 32733606 · NCT06304441
  • Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    J Thorac Oncol · 2021 · PMID 31887431 · NCT07361705
  • A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Lung Cancer · 2020 · PMID 31027690 · NCT07361705
  • Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    J Clin Oncol · 2020 · PMID 31809241 · NCT06304441
  • A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.
    Front Oncol · 2020 · PMID 31544065 · NCT06304441

Lung Neoplasms (18)

  • Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    JCO Precis Oncol · 2025 · PMID 41066729 · NCT02465060
  • PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    JCO Precis Oncol · 2025 · PMID 40865033 · NCT02465060
  • Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol · 2025 · PMID 39615497 · NCT05624996
  • Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    JCO Precis Oncol · 2025 · PMID 39913886 · NCT02465060
  • Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.
    Future Oncol · 2025 · PMID 41236484 · NCT06194448

Neoplasm Metastasis (7)

  • Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer · 2019 · PMID 29438373 · NCT04770688
  • Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Lancet Respir Med · 2018 · PMID 28408243 · NCT04770688
  • A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer · 2018 · PMID 29290249 · NCT04770688
  • Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    J Thorac Oncol · 2016 · PMID 25695221 · NCT04770688
  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Lancet Oncol · 2015 · PMID 25175099 · NCT04770688

Neoplasms (3)

  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    J Clin Oncol · 2023 · PMID 36288547 · NCT02099058
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res · 2022 · PMID 34426443 · NCT02099058
  • First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    J Clin Oncol · 2019 · PMID 30285518 · NCT02099058

Mesothelioma (1)

Publications by journal

Trial-results highlights

Clinical trials have investigated the effectiveness of osimertinib in various settings. In the NCT02151981 (AURA3) study, progression-free survival (PFS) by investigator assessment was a median of 10.1 Months for the osimertinib 80mg arm, compared to 4.4 Months for the chemotherapy arm. For non-small-cell lung carcinoma, the NCT03521154 (LAURA) trial reported a median progression-free survival by blinded independent central review (BICR) of 39.13 Months for the osimertinib arm, versus 5.55 Months for the placebo arm. The NCT04035486 (FLAURA2) study, also in non-small-cell lung carcinoma, showed a median PFS of 16.7 Months for the AZD9291 (osimertinib) arm and 25.5 Months for the AZD9291 + Chemo arm. A sensitivity analysis for PFS by BICR in the same study reported a median of 19.9 Months for the AZD9291 arm and 29.4 Months for the AZD9291 + Chemo arm.

Further investigations into non-small-cell lung carcinoma include the NCT04487080 (MARIPOSA) trial, which assessed progression-free survival according to RECIST version 1.1 as assessed by BICR. In this study, the osimertinib + placebo matching lazertinib arm reported a median PFS of 16.59 Months. For comparison, the amivantamab + lazertinib arm had a median PFS of 23.72 Months, and the lazertinib + placebo matching osimertinib arm had a median PFS of 18.46 Months.

All values presented are sourced from primary registry reporting. For clinical decisions, individual study publications should be consulted.

All Osimertinib publications (261)

2026 (9 papers)

  1. Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
    Yang JC, Chen YM, Batra U, et al. · Clin Lung Cancer · 2026 · Derived
    PubMed: PMID 41308232 · NCT03778229 (SAVANNAH) · Carcinoma, Non-Small-Cell Lung
  2. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Riess JW, Yu HA, Le X, et al. · Ann Oncol · 2026 · Derived
    PubMed: PMID 41780641 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  3. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
    Nishio M, Seto T, Reck M, et al. · JTO Clin Res Rep · 2026 · Derived
    PubMed: PMID 40458541 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  4. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lu S, Wang J, Yang N, et al. · Lancet · 2026 · Derived
    PubMed: PMID 41544643 · NCT05015608 (SACHI) · Carcinoma, Non-Small-Cell Lung
  5. A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
    Lu S, Kato T, Dong X, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 42037107 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  6. Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
    Li A, Feng WN, Li J, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41530133 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  7. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.
    Lee CK, Lefresne S, Soon YY, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41534788 · NCT03769103 · Carcinoma, Non-Small-Cell Lung
  8. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
    Arriola E, Casarini I, Özgüroğlu M, et al. · Eur J Cancer · 2026 · Derived
    PubMed: PMID 42019226 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  9. Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.
    Spira AI, Berz D, Jotte RM, et al. · Clin Lung Cancer · 2026 · Background
    PubMed: PMID 41385873 · NCT04486833 (Acclaim-1) · Carcinoma, Non-Small-Cell Lung

2025 (23 papers)

  1. A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
    Middleton G, Robbins HL, Fletcher P, et al. · NPJ Precis Oncol · 2025 · Trial result
    PubMed: PMID 40069402 · NCT02664935 · Carcinoma, Non-Small-Cell Lung
  2. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
    Yap TA, Kwiatkowski DJ, Dagogo-Jack I, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41111090 · NCT04665206 · Mesothelioma
  3. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
    Yang JC, Lu S, Hayashi H, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40923797 · NCT04487080 (MARIPOSA) · Carcinoma, Non-Small-Cell Lung
  4. Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.
    Xu Z, Li Y, Wang L, et al. · Expert Rev Anticancer Ther · 2025 · Derived
    PubMed: PMID 38526910 · NCT05458726 · Carcinoma, Non-Small-Cell Lung
  5. Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.
    Wang X, Li Z, Wang L, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40234867 · NCT04029350 (ALTN-03) · Carcinoma, Non-Small-Cell Lung
  6. Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    Tsao AS, Song Z, Ho AL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41066729 · NCT02465060 · Lung Neoplasms
  7. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib.
    Tan DS, Nadal E, Cheema P, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 41466843 · NCT06417814 (TROPION-Lung15) · Carcinoma, Non-Small-Cell Lung
  8. Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Sampath S, Rashdan S, Iyengar P, et al. · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 41054436 · NCT03667820 · Carcinoma, Non-Small-Cell Lung
  9. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
    Riess JW, de Langen AJ, Ponce S, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40466026 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  10. RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
    Nishino K, Seto T, Nishio M, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40995949 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  11. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    Nakagawa K, Garon EB, Seto T, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39622410 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  12. EGFR mutation testing across the osimertinib clinical program.
    Murat-Onana ML, Ramalingam SS, Jänne PA, et al. · Lung Cancer · 2025 · Derived
    PubMed: PMID 40311309 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  13. Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment.
    Markovets A, Merino Vega D, Abbosh C, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41166679 · NCT02151981 (AURA3)
  14. Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
    Lee JB, Choi SJ, Shim HS, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39732365 · NCT04351555 (NeoADAURA) · Carcinoma, Non-Small-Cell Lung
  15. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
    Le X, Patel JD, Shum E, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39378386 · NCT03909334 · Carcinoma, Non-Small-Cell Lung
  16. JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.
    Kang D, Wang Y, Lin Y, et al. · Clin Cancer Res · 2025 · Derived
    PubMed: PMID 40333694 · NCT04720976
  17. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
    Jänne PA, Planchard D, Kobayashi K, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 41104938 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  18. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    Janku F, Jegede OA, Puhalla SL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40865033 · NCT02465060 · Lung Neoplasms
  19. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH, Mileham KF, Robinson MM, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39615497 · NCT05624996 · Lung Neoplasms
  20. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
    He J, Tsuboi M, Weder W, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40454705 · NCT04351555 (NeoADAURA) · Carcinoma, Non-Small-Cell Lung
  21. Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    Gouda MA, Wei Z, Rodon J, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 39913886 · NCT02465060 · Lung Neoplasms
  22. Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.
    Aredo JV, Peled N, Arriola E, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 41236484 · NCT06194448 (NEOLA) · Lung Neoplasms
  23. Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design.
    Chen X, Zhang D, Xue J, et al. · Discov Oncol · 2025 · Background
    PubMed: PMID 40608215 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2024 (20 papers)

  1. Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
    Schuler M, Hense J, Darwiche K, et al. · J Nucl Med · 2024 · Trial result
    PubMed: PMID 38575188 · NCT03810066
  2. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Wu YL, Guarneri V, Voon PJ, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39089305 · NCT03940703 · Carcinoma, Non-Small-Cell Lung
  3. Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors.
    Tu CY, Hsia TC, Lin YC, et al. · Can Respir J · 2024 · Derived
    PubMed: PMID 38476120 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  4. Revolutionizing cancer drug development: Harnessing the potential of basket trials.
    Subbiah V, Burris HA, Kurzrock R, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37934000 · NCT02465060 · Lung Neoplasms
  5. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
    Soo RA, de Marinis F, Han JY, et al. · Clin Lung Cancer · 2024 · Derived
    PubMed: PMID 37914594 · NCT05526755 (TARGET)
  6. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
    Remon J, Besse B, Aix SP, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38324744 · NCT02856893 (APPLE)
  7. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Pasello G, Lorenzi M, Scattolin D, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 38520745 · NCT04965701 (FLOWER)
  8. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    Park S, Baldry R, Jung HA, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38828959 · NCT04563871 (BLOSSOM) · Carcinoma, Non-Small-Cell Lung
  9. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
    Lu S, Kato T, Dong X, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38828946 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  10. A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
    Kim YJ, Kim S, Kim TM, et al. · Lung Cancer · 2024 · Derived
    PubMed: PMID 38986212 · NCT03414814 · Carcinoma, Non-Small-Cell Lung
  11. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    Jänne PA, Planchard D, Kobayashi K, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38042525 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  12. Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
    Gien LT, Song Z, Poklepovic A, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39666929 · NCT02465060 · Lung Neoplasms
  13. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
    Cho BC, Lu S, Felip E, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38924756 · NCT04487080 (MARIPOSA) · Carcinoma, Non-Small-Cell Lung
  14. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    Blakely CM, Urisman A, Gubens MA, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39028931 · NCT03433469 · Carcinoma, Non-Small-Cell Lung
  15. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
    Vokes NI, Le X, Yap TA, et al. · Clin Cancer Res · 2024 · Background
    PubMed: PMID 39018064 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  16. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy.
    Sirico M, D'Angelo A, Gianni C, et al. · Cancers (Basel) · 2024 · Background
    PubMed: PMID 36765661 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  17. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Reungwetwattana T, Nakagawa K, Cho BC, et al. · J Clin Oncol · 2024 · Background
    PubMed: PMID 30153097 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  18. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Passaro A, Wang J, Wang Y, et al. · Ann Oncol · 2024 · Background
    PubMed: PMID 37879444 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  19. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    Mok T, Nakagawa K, Park K, et al. · J Clin Oncol · 2024 · Background
    PubMed: PMID 38252907 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  20. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.
    Grazini U, Markovets A, Ireland L, et al. · Clin Cancer Res · 2024 · Background
    PubMed: PMID 38630555 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2023 (16 papers)

  1. Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
    Morgillo F, Della Corte CM, Fasano M, et al. · ESMO Open · 2023 · Trial result
    PubMed: PMID 27843613 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
    Kim C, Xi L, Cultraro CM, et al. · Cancers (Basel) · 2023 · Trial result
    PubMed: PMID 34283064 · NCT02759835 · Lung Neoplasms
  3. Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
    Zhang L, You Y, Liu X, et al. · Thorac Cancer · 2023 · Derived
    PubMed: PMID 37016906 · NCT05104281 · Carcinoma, Non-Small-Cell Lung
  4. Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
    Yang JC, Su WC, Chiu CH, et al. · Invest New Drugs · 2023 · Derived
    PubMed: PMID 36892745 · NCT03255083 · Carcinoma, Non-Small-Cell Lung
  5. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
    Wisinski KB, Flamand Y, Wilson MA, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37053535 · NCT02465060 · Lung Neoplasms
  6. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    Planchard D, Jänne PA, Cheng Y, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37937763 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  7. The NCI-MATCH trial: lessons for precision oncology.
    O'Dwyer PJ, Gray RJ, Flaherty KT, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37322121 · NCT02465060 · Lung Neoplasms
  8. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
    Nishio K, Sakai K, Nishio M, et al. · Transl Lung Cancer Res · 2023 · Derived
    PubMed: PMID 37691865 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  9. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
    Kim DW, Kim SW, Camidge DR, et al. · J Thorac Oncol · 2023 · Derived
    PubMed: PMID 36641093 · NCT03381274 · Carcinoma, Non-Small-Cell Lung
  10. Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.
    Hallick J, Baird AM, Falchook G, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36999526 · NCT03940703 · Carcinoma, Non-Small-Cell Lung
  11. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB, Reck M, Nishio K, et al. · ESMO Open · 2023 · Derived
    PubMed: PMID 37390764 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  12. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
    Chiu CH, Lin MC, Wei YF, et al. · Target Oncol · 2023 · Derived
    PubMed: PMID 37329423 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  13. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    Camidge DR, Barlesi F, Goldman JW, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36288547 · NCT02099058 · Neoplasms
  14. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
    Veerman GDM, Boosman RJ, Jebbink M, et al. · EClinicalMedicine · 2023 · Background
    PubMed: PMID 37125403 · NCT07485452 (OSIBBBOOST) · Carcinoma, Non-Small-Cell Lung
  15. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators.
    Marrocco I, Yarden Y · Cancers (Basel) · 2023 · Background
    PubMed: PMID 37894376 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  16. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
    Choudhury NJ, Marra A, Sui JSY, et al. · J Thorac Oncol · 2023 · Background
    PubMed: PMID 36494075 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2022 (25 papers)

  1. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
    Roper N, Brown AL, Wei JS, et al. · Cell Rep Med · 2022 · Trial result
    PubMed: PMID 32483558 · NCT02759835 · Lung Neoplasms
  2. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
    Yu HA, Paz-Ares LG, Yang JC, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33046516 · NCT02789345 · Carcinoma, Non-Small-Cell Lung
  3. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Yu HA, Goldberg SB, Le X, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34389237 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  4. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
    Tsuboi M, Weder W, Escriu C, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 34278827 · NCT04351555 (NeoADAURA) · Carcinoma, Non-Small-Cell Lung
  5. An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib.
    Singh J, Bourke S, Dyer M, et al. · Value Health · 2022 · Derived
    PubMed: PMID 35379563 · NCT02151981 (AURA3)
  6. Platelet p110β mediates platelet-leukocyte interaction and curtails bacterial dissemination in pneumococcal pneumonia.
    Schrottmaier WC, Kral-Pointner JB, Salzmann M, et al. · Cell Rep · 2022 · Derived
    PubMed: PMID 36351402 · NCT02465060 · Lung Neoplasms
  7. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Popat S, Hsia TC, Hung JY, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35274704 · NCT04179890 (UpSwinG) · Carcinoma, Non-Small-Cell Lung
  8. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
    Nishio M, Nishio K, Reck M, et al. · JTO Clin Res Rep · 2022 · Derived
    PubMed: PMID 35369607 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  9. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Nakagawa K, Garon EB, Gao L, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35841410 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  10. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
    Nadal E, Horinouchi H, Shih JY, et al. · Drug Saf · 2022 · Derived
    PubMed: PMID 34928484 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  11. Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.
    Malik PS, Noronha V, Dabkara D, et al. · Indian J Cancer · 2022 · Derived
    PubMed: PMID 35343187 · NCT03853551 · Carcinoma, Non-Small-Cell Lung
  12. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Lu S, Casarini I, Kato T, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 33558193 · NCT03521154 (LAURA) · Carcinoma, Non-Small-Cell Lung
  13. Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
    Li A, Chen HJ, Yang JJ, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 36333268 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  14. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
    Krop IE, Jegede OA, Grilley-Olson JE, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 35138919 · NCT02465060 · Lung Neoplasms
  15. Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events.
    King-Kallimanis BL, Bhatnagar V, Horodniceanu EG, et al. · Clin Trials · 2022 · Derived
    PubMed: PMID 35575012 · NCT02151981 (AURA3)
  16. A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
    Kim C, Liu SV, Crawford J, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34568058 · NCT02954523 · Carcinoma, Non-Small-Cell Lung
  17. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    Damodaran S, Zhao F, Deming DA, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35133871 · NCT02465060 · Lung Neoplasms
  18. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC, Felip E, Hayashi H, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 34911336 · NCT04487080 (MARIPOSA) · Carcinoma, Non-Small-Cell Lung
  19. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Camidge DR, Morgensztern D, Heist RS, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34426443 · NCT02099058 · Neoplasms
  20. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study.
    Pan Z, Yang G, He H, et al. · Ther Adv Med Oncol · 2022 · Background
    PubMed: PMID 32733606 · NCT06304441 · Meningeal Carcinomatosis
  21. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.
    Liu Y, Sun L, Xiong ZC, et al. · Onco Targets Ther · 2022 · Background
    PubMed: PMID 28479857 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  22. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
    F Smit E, Dooms C, Raskin J, et al. · Future Oncol · 2022 · Background
    PubMed: PMID 34918545 · NCT03940703 · Carcinoma, Non-Small-Cell Lung
  23. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Dunn S, Eberlein C, Yu J, et al. · Oncogene · 2022 · Background
    PubMed: PMID 36241868 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  24. Non-small cell lung cancer in China.
    Chen P, Liu Y, Wen Y, et al. · Cancer Commun (Lond) · 2022 · Background
    PubMed: PMID 36075878 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  25. Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli E, De Carlo E, Del Conte A, et al. · Int J Mol Sci · 2022 · Background
    PubMed: PMID 35805940 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2021 (20 papers)

  1. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    Ahn MJ, Chiu CH, Cheng Y, et al. · J Thorac Oncol · 2021 · Trial result
    PubMed: PMID 31887431 · NCT07361705 · Meningeal Carcinomatosis
  2. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
    Yu HA, Schoenfeld AJ, Makhnin A, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32463456 · NCT02803203 · Carcinoma, Non-Small-Cell Lung
  3. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    White MN, Piotrowska Z, Stirling K, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33610453 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  4. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
    Vishwanathan K, Sanchez-Simon I, Keam B, et al. · Pharmacol Res Perspect · 2021 · Derived
    PubMed: PMID 32567817 · NCT02923947 · Renal Insufficiency
  5. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    Provencio M, Terrasa J, Garrido P, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 33676426 · NCT03790397 (OSIREX) · Carcinoma, Non-Small-Cell Lung
  6. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
    Poels KE, Schoenfeld AJ, Makhnin A, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34140482 · NCT03810807 · Carcinoma, Non-Small-Cell Lung
  7. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
    Planchard D, Feng PH, Karaseva N, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 34543864 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  8. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA, Mok TS, Han JY, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32861806 · NCT02151981 (AURA3)
  9. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
    Mitani S, Chen Y, Inoue K, et al. · Gan To Kagaku Ryoho · 2021 · Derived
    PubMed: PMID 34795131 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  10. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.
    Majem M, Sullivan I, Viteri S, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34763195 · NCT02841579 (AZENT) · Carcinoma, Non-Small-Cell Lung
  11. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
    Hochmair MJ, Morabito A, Hao D, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 32854536 · NCT03370770 · Carcinoma, Non-Small-Cell Lung
  12. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
    Flaherty KT, Gray RJ, Chen AP, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33048619 · NCT02465060 · Lung Neoplasms
  13. Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis.
    Feinberg B, Halmos B, Gucalp R, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 32757853 · NCT03370770 · Carcinoma, Non-Small-Cell Lung
  14. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Deng Z, Qin Y, Liu Y, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33067126 · NCT02971501 · Carcinoma, Non-Small-Cell Lung
  15. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
    Chae YK, Hong F, Vaklavas C, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32463741 · NCT02465060 · Lung Neoplasms
  16. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
    Bennouna J, Girard N, Audigier-Valette C, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 31648999 · NCT03865511 (MELROSE) · Carcinoma, Non-Small-Cell Lung
  17. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H, Tanaka K, Morita S, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33199228 · NCT04035486 (FLAURA2) · Carcinoma, Non-Small-Cell Lung
  18. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A, Palafox M, Monserrat L, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 32220884 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  19. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    Duan J, Xu J, Wang Z, et al. · J Thorac Oncol · 2021 · Background
    PubMed: PMID 32916309 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  20. Understanding the Global Cancer Statistics 2018: implications for cancer control.
    Cai Z, Liu Q · Sci China Life Sci · 2021 · Background
    PubMed: PMID 31463738 · NCT04148898 (OWONBNSCLCLM) · Carcinoma, Non-Small-Cell Lung

2020 (23 papers)

  1. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K, Li YS, Zheng MM, et al. · Lung Cancer · 2020 · Trial result
    PubMed: PMID 31027690 · NCT07361705 · Meningeal Carcinomatosis
  2. Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.
    Sheng J, Fang W, Liu X, et al. · Onco Targets Ther · 2020 · Trial result
    PubMed: PMID 28260924 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Saito H, Fukuhara T, Furuya N, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 30975627 · NCT04029350 (ALTN-03) · Carcinoma, Non-Small-Cell Lung
  4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    Ramalingam SS, Vansteenkiste J, Planchard D, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 31751012 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  5. The National Lung Matrix Trial of personalized therapy in lung cancer.
    Middleton G, Fletcher P, Popat S, et al. · Nature · 2020 · Trial result
    PubMed: PMID 32669708 · NCT02664935 · Carcinoma, Non-Small-Cell Lung
  6. Detection value of tumor cells in cerebrospinal fluid in the diagnosis of meningeal metastasis from lung cancer by immuno-FISH technology.
    Lv Y, Mu N, Ma C, et al. · Oncol Lett · 2020 · Trial result
    PubMed: PMID 28105214 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  7. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.
    Gregorc V, Lazzari C, Karachaliou N, et al. · Transl Lung Cancer Res · 2020 · Trial result
    PubMed: PMID 29782558 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  8. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
    Flippot R, Biondani P, Auclin E, et al. · J Thorac Oncol · 2020 · Trial result
    PubMed: PMID 31108248 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  9. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
    Chang N, Duan J, Wang L, et al. · Oncol Lett · 2020 · Trial result
    PubMed: PMID 32782544 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  10. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
    Akamatsu H, Teraoka S, Morita S, et al. · Clin Lung Cancer · 2020 · Trial result
    PubMed: PMID 31085043 · NCT04029350 (ALTN-03) · Carcinoma, Non-Small-Cell Lung
  11. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N, Mera T, Märten A, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 31863283 · NCT03370770 · Carcinoma, Non-Small-Cell Lung
  12. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Schmid S, Früh M, Peters S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32027845 · NCT03778229 (SAVANNAH) · Carcinoma, Non-Small-Cell Lung
  13. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. · Cancer · 2020 · Derived
    PubMed: PMID 31769875 · NCT02151981 (AURA3)
  14. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K, Garon EB, Seto T, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31591063 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  15. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
    Hochmair MJ, Morabito A, Hao D, et al. · Future Oncol · 2020 · Derived
    PubMed: PMID 31370698 · NCT03370770 · Carcinoma, Non-Small-Cell Lung
  16. Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.
    Cao Y, Qiu X, Xiao G, et al. · PLoS One · 2020 · Derived
    PubMed: PMID 31442277 · NCT03133234
  17. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    Yang JCH, Kim SW, Kim DW, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31809241 · NCT06304441 · Meningeal Carcinomatosis
  18. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV, Han JY, Ahn MJ, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32027846 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  19. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.
    Pan Z, Yang G, Cui J, et al. · Front Oncol · 2020 · Background
    PubMed: PMID 31544065 · NCT06304441 · Meningeal Carcinomatosis
  20. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S, Fatherree JP, Cortez E, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30327306 · NCT04908956 (STEREO) · Carcinoma, Non-Small-Cell Lung
  21. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Leonetti A, Sharma S, Minari R, et al. · Br J Cancer · 2020 · Background
    PubMed: PMID 31564718 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  22. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY, Lim TH, Lim J, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 30676858 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  23. Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis.
    Chen Y, Huang L, Dong Y, et al. · Front Cell Dev Biol · 2020 · Background
    PubMed: PMID 33123537 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2019 (21 papers)

  1. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL, Ahn MJ, Garassino MC, et al. · J Clin Oncol · 2019 · Trial result
    PubMed: PMID 30059262 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  2. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.
    Hochmair M · Target Oncol · 2019 · Trial result
    PubMed: PMID 29700687 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  3. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B, Li K, Zhao Y, et al. · Br J Cancer · 2019 · Trial result
    PubMed: PMID 29438373 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  4. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
    Ahn MJ, Tsai CM, Shepherd FA, et al. · Cancer · 2019 · Trial result
    PubMed: PMID 30512189 · NCT07361705 · Meningeal Carcinomatosis
  5. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH, Weekes CD, Nemunaitis J, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30285518 · NCT02099058 · Neoplasms
  6. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M, Garon EB, Paz-Ares L, et al. · Clin Lung Cancer · 2019 · Derived
    PubMed: PMID 29317191 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  7. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Nie K, Zhang Z, Zhang C, et al. · Lung Cancer · 2019 · Derived
    PubMed: PMID 29858027 · NCT02959749
  8. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.
    Lee CK, Novello S, Rydén A, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29733770 · NCT02151981 (AURA3)
  9. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
    Hochmair MJ, Morabito A, Hao D, et al. · Future Oncol · 2019 · Derived
    PubMed: PMID 30336693 · NCT03370770 · Carcinoma, Non-Small-Cell Lung
  10. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
    Yu HA, Suzawa K, Jordan E, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29530932 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  11. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL, Zhao Q, Deng L, et al. · Lung Cancer · 2019 · Background
    PubMed: PMID 30642536 · NCT04148898 (OWONBNSCLCLM) · Carcinoma, Non-Small-Cell Lung
  12. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z, Cheng Y, An T, et al. · Lancet Respir Med · 2019 · Background
    PubMed: PMID 30017884 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  13. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F, Diao XY, Zhang X, et al. · Cancer Commun (Lond) · 2019 · Background
    PubMed: PMID 30823937 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  14. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
    Shah KN, Bhatt R, Rotow J, et al. · Nat Med · 2019 · Background
    PubMed: PMID 30478424 · NCT04085315
  15. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
    Palma DA, Olson R, Harrow S, et al. · Lancet · 2019 · Background
    PubMed: PMID 30982687 · NCT04908956 (STEREO) · Carcinoma, Non-Small-Cell Lung
  16. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
    Minari R, Bordi P, La Monica S, et al. · J Thorac Oncol · 2019 · Background
    PubMed: PMID 29596911 · NCT03543683 · Carcinoma, Non-Small-Cell Lung
  17. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    John T, Akamatsu H, Delmonte A, et al. · Lung Cancer · 2019 · Background
    PubMed: PMID 30527177 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  18. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T, Chu Q, Wang H, et al. · Int J Cancer · 2019 · Background
    PubMed: PMID 30387880 · NCT04148898 (OWONBNSCLCLM) · Carcinoma, Non-Small-Cell Lung
  19. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Iyengar P, Wardak Z, Gerber DE, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 28973074 · NCT04908956 (STEREO) · Carcinoma, Non-Small-Cell Lung
  20. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S, Gao F, Fu S, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 29596544 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  21. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    Han B, Li K, Wang Q, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 30098152 · NCT04029350 (ALTN-03) · Carcinoma, Non-Small-Cell Lung

2018 (15 papers)

  1. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q, Song Y, Zhang X, et al. · BMC Cancer · 2018 · Trial result
    PubMed: PMID 28673332 · NCT07361705 · Meningeal Carcinomatosis
  2. Estimates of cancer incidence and mortality in China, 2013.
    Zheng R, Zeng H, Zhang S, et al. · Chin J Cancer · 2018 · Trial result
    PubMed: PMID 28818111 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  3. Leptomeningeal metastasis.
    Taillibert S, Chamberlain MC · Handb Clin Neurol · 2018 · Trial result
    PubMed: PMID 29307353 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  4. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, et al. · N Engl J Med · 2018 · Trial result
    PubMed: PMID 29151359 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  5. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P, Oh YT, Deng L, et al. · Clin Cancer Res · 2018 · Trial result
    PubMed: PMID 28765329 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  6. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R, Dafni U, Felip E, et al. · Lancet Respir Med · 2018 · Trial result
    PubMed: PMID 28408243 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  7. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T, Nogami N, Kozuki T, et al. · Lung Cancer · 2018 · Trial result
    PubMed: PMID 29290249 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  8. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
    Masuda C, Yanagisawa M, Yorozu K, et al. · Int J Oncol · 2018 · Trial result
    PubMed: PMID 28627678 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  9. The anti-tumor effect of aspirin: What we know and what we expect.
    Ma J, Cai Z, Wei H, et al. · Biomed Pharmacother · 2018 · Trial result
    PubMed: PMID 28881293 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  10. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.
    Le Rhun E, Weller M, Brandsma D, et al. · Ann Oncol · 2018 · Trial result
    PubMed: PMID 28881917 · NCT07361705 · Meningeal Carcinomatosis
  11. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P, Yates JW, Yang Z, et al. · Clin Cancer Res · 2018 · Trial result
    PubMed: PMID 27435396 · NCT07361705 · Meningeal Carcinomatosis
  12. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H, Katakami N, Okamoto I, et al. · Cancer Sci · 2018 · Derived
    PubMed: PMID 29697876 · NCT02151981 (AURA3)
  13. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
    Jenkins S, Yang JC, Jänne PA, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 28527899 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  14. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
    Gainor JF, Niederst MJ, Lennerz JK, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 26988570 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  15. Leptomeningeal metastases in non-small-cell lung cancer.
    Cheng H, Perez-Soler R · Lancet Oncol · 2018 · Background
    PubMed: PMID 29304362 · NCT04148898 (OWONBNSCLCLM) · Carcinoma, Non-Small-Cell Lung

2017 (8 papers)

  1. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS, Wu Y-L, Ahn M-J, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 27959700 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  2. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Li S, Dai W, Mo W, et al. · Int J Cancer · 2017 · Trial result
    PubMed: PMID 28857200 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  3. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G, Tsai CM, Shepherd FA, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27751847 · NCT07361705 · Meningeal Carcinomatosis
  4. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
    Garon EB, Reck M, Paz-Ares L, et al. · Clin Lung Cancer · 2017 · Derived
    PubMed: PMID 27894601 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  5. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
    Lynch JT, McEwen R, Crafter C, et al. · Oncotarget · 2017 · Background
    PubMed: PMID 26989080 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  6. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
    Jacobsen K, Bertran-Alamillo J, Molina MA, et al. · Nat Commun · 2017 · Background
    PubMed: PMID 28871105 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  7. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK, Halabi S, Sanford BL, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28199818 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  8. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
    Blakely CM, Watkins TBK, Wu W, et al. · Nat Genet · 2017 · Background
    PubMed: PMID 29106415 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2016 (11 papers)

  1. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q, Liu XY, Zhang T, et al. · Hum Immunol · 2016 · Trial result
    PubMed: PMID 25305457 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
    Liao BC, Lee JH, Lin CC, et al. · J Thorac Oncol · 2016 · Trial result
    PubMed: PMID 26334749 · NCT07361705 · Meningeal Carcinomatosis
  3. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.
    Iuchi T, Shingyoji M, Itakura M, et al. · Int J Clin Oncol · 2016 · Trial result
    PubMed: PMID 25336382 · NCT07361705 · Meningeal Carcinomatosis
  4. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E, Hotta K, Nogami N, et al. · J Thorac Oncol · 2016 · Trial result
    PubMed: PMID 25695221 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  5. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA, Ashton SE, Ghiorghiu S, et al. · Cancer Discov · 2016 · Trial result
    PubMed: PMID 24893891 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  6. Is the NCI MATCH trial a match for gynecologic oncology?
    Moore KN, Mannel RS · Gynecol Oncol · 2016 · Derived
    PubMed: PMID 26586415 · NCT02465060 · Lung Neoplasms
  7. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.
    Wang J, Wang B, Chu H, et al. · Onco Targets Ther · 2016 · Background
    PubMed: PMID 27382309 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  8. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 26410619 · NCT02664935 · Carcinoma, Non-Small-Cell Lung
  9. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Masters GA, Temin S, Azzoli CG, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26324367 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  10. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C, Malanga D, Rinaldo N, et al. · Oncotarget · 2016 · Background
    PubMed: PMID 26053093 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  11. Cancer statistics in China, 2015.
    Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26808342 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2015 (12 papers)

  1. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, et al. · Lancet Oncol · 2015 · Trial result
    PubMed: PMID 25175099 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  2. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L, Han R, Xiao H, et al. · Clin Cancer Res · 2015 · Trial result
    PubMed: PMID 24644001 · NCT04184921 · Carcinoma, Non-Small-Cell Lung
  3. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Trial result
    PubMed: PMID 25747273 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. NK cell phenotypic modulation in lung cancer environment.
    Jin S, Deng Y, Hao JW, et al. · PLoS One · 2015 · Trial result
    PubMed: PMID 25299645 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  5. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA, Yang JC, Kim DW, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25923549 · NCT07361705 · Meningeal Carcinomatosis
  6. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 26159065 · NCT02151981 (AURA3)
  7. Lung cancer molecular epidemiology in China: recent trends.
    Zhou C · Transl Lung Cancer Res · 2015 · Background
    PubMed: PMID 25806311 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  8. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.
    Yip PY · Transl Lung Cancer Res · 2015 · Background
    PubMed: PMID 25870799 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  9. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Reck M, Popat S, Reinmuth N, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 25115305 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  10. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
    Holland WS, Chinn DC, Lara PN, et al. · J Cancer Res Clin Oncol · 2015 · Background
    PubMed: PMID 25323938 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  11. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
    Finlay MR, Anderton M, Ashton S, et al. · J Med Chem · 2015 · Background
    PubMed: PMID 25271963 · NCT03133546 (BOOSTER)
  12. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
    Bokobza SM, Jiang Y, Weber AM, et al. · Oncotarget · 2015 · Background
    PubMed: PMID 24946858 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2014 (8 papers)

  1. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
    Shi SB, Tang XY, Tian J, et al. · J Immunother · 2014 · Trial result
    PubMed: PMID 24714359 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
    He S, Yin T, Li D, et al. · J Transl Med · 2014 · Trial result
    PubMed: PMID 23937717 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
    Shi Y, Au JS, Thongprasert S, et al. · J Thorac Oncol · 2014 · Background
    PubMed: PMID 24419411 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  4. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
    Sequist LV, Yang JC, Yamamoto N, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 23816960 · NCT02769286 (LiquidLung-O) · Lung Neoplasms
  5. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H, Dai G, Weng J, et al. · J Med Chem · 2014 · Background
    PubMed: PMID 25148209 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  6. PI3K and cancer: lessons, challenges and opportunities.
    Fruman DA, Rommel C · Nat Rev Drug Discov · 2014 · Background
    PubMed: PMID 24481312 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  7. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
    Fei SJ, Zhang XC, Dong S, et al. · PLoS One · 2014 · Background
    PubMed: PMID 23874880 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  8. Acquired resistance to TKIs in solid tumours: learning from lung cancer.
    Camidge DR, Pao W, Sequist LV, et al. · Nat Rev Clin Oncol · 2014 · Background
    PubMed: PMID 24981256 · NCT03133546 (BOOSTER)

2013 (3 papers)

  1. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
    Ware KE, Hinz TK, Kleczko E, et al. · Oncogenesis · 2013 · Trial result
    PubMed: PMID 23552882 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
    Weickhardt AJ, Scheier B, Burke JM, et al. · J Thorac Oncol · 2013 · Background
    PubMed: PMID 23154552 · NCT04908956 (STEREO) · Carcinoma, Non-Small-Cell Lung
  3. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
    Gahr S, Stoehr R, Geissinger E, et al. · Br J Cancer · 2013 · Background
    PubMed: PMID 24002608 · NCT06557096 · Carcinoma, Non-Small-Cell Lung

2012 (7 papers)

  1. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
    Umemura S, Tsubouchi K, Yoshioka H, et al. · Lung Cancer · 2012 · Trial result
    PubMed: PMID 22487432 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung
  2. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
    Parkhurst MR, Riley JP, Dudley ME, et al. · Clin Cancer Res · 2012 · Trial result
    PubMed: PMID 21844012 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
    Beijers AJ, Jongen JL, Vreugdenhil G, et al. · Neth J Med · 2012 · Trial result
    PubMed: PMID 22271810 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A, Crombag L, Heideman DA, et al. · Eur J Cancer · 2012 · Trial result
    PubMed: PMID 21784628 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  5. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY, Chen HY, Li KC, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22215752 · NCT04391283 · Carcinoma, Non-Small-Cell Lung
  6. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R, Carcereny E, Gervais R, et al. · Lancet Oncol · 2012 · Background
    PubMed: PMID 22285168 · NCT03133546 (BOOSTER)
  7. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
    Davies BR, Greenwood H, Dudley P, et al. · Mol Cancer Ther · 2012 · Background
    PubMed: PMID 22294718 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

2011 (8 papers)

  1. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
    Porta R, Sánchez-Torres JM, Paz-Ares L, et al. · Eur Respir J · 2011 · Trial result
    PubMed: PMID 20595147 · NCT04770688 (AUTOMAN) · Neoplasm Metastasis
  2. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q, Wang W, Li Y, et al. · Int Immunopharmacol · 2011 · Trial result
    PubMed: PMID 21215350 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
    Kim H, Kim SH, Kim MJ, et al. · J Immunother · 2011 · Trial result
    PubMed: PMID 21499124 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M, Wu YL, Thongprasert S, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21670455 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  5. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
    Eichler AF, Kahle KT, Wang DL, et al. · Neuro Oncol · 2011 · Trial result
    PubMed: PMID 20627894 · NCT07361705 · Meningeal Carcinomatosis
  6. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
    Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al. · Immunol Rev · 2011 · Trial result
    PubMed: PMID 21488898 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  7. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
    Oxnard GR, Arcila ME, Sima CS, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21135146 · NCT03133546 (BOOSTER)
  8. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
    Arcila ME, Oxnard GR, Nafa K, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21248300 · NCT04391283 · Carcinoma, Non-Small-Cell Lung

2010 (5 papers)

  1. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20818862 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.
    Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. · Clin Transl Oncol · 2010 · Trial result
    PubMed: PMID 20156778 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20573926 · NCT06557096 · Carcinoma, Non-Small-Cell Lung
  4. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman D, Pao W, Riely GJ, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 19949011 · NCT03255083 · Carcinoma, Non-Small-Cell Lung
  5. Implications of key trials in advanced nonsmall cell lung cancer.
    Bonomi PD · Cancer · 2010 · Background
    PubMed: PMID 20087963 · NCT03133546 (BOOSTER)

2009 (4 papers)

  1. Skin metastases from lung cancer.
    Mollet TW, Garcia CA, Koester G, et al. · Dermatol Online J · 2009 · Trial result
    PubMed: PMID 19624979 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
    Jackman DM, Miller VA, Cioffredi LA, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19671843 · NCT03133546 (BOOSTER)
  3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung
  4. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
    Burtness B, Anadkat M, Basti S, et al. · J Natl Compr Canc Netw · 2009 · Background
    PubMed: PMID 19470276 · NCT06557096 · Carcinoma, Non-Small-Cell Lung

2008 (4 papers)

  1. Epitope landscape in breast and colorectal cancer.
    Segal NH, Parsons DW, Peggs KS, et al. · Cancer Res · 2008 · Trial result
    PubMed: PMID 18245491 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Next generation of immunotherapy for melanoma.
    Kirkwood JM, Tarhini AA, Panelli MC, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18612161 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH, Chien CR, Chang YL, et al. · Clin Cancer Res · 2008 · Trial result
    PubMed: PMID 18172267 · NCT07361705 · Meningeal Carcinomatosis
  4. The role of the EGFR signaling in tumor microenvironment.
    De Luca A, Carotenuto A, Rachiglio A, et al. · J Cell Physiol · 2008 · Trial result
    PubMed: PMID 17894407 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung

2007 (2 papers)

  1. Potential therapeutic role of natural killer cells in cancer.
    Woan K, Reddy V · Expert Opin Biol Ther · 2007 · Trial result
    PubMed: PMID 17150016 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J · Mol Cancer Res · 2007 · Trial result
    PubMed: PMID 17374728 · NCT04425681 (OWBLM) · Carcinoma, Non-Small-Cell Lung

2006 (4 papers)

  1. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
    Seino K, Motohashi S, Fujisawa T, et al. · Cancer Sci · 2006 · Trial result
    PubMed: PMID 16805854 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Cancer stem cells.
    Jordan CT, Guzman ML, Noble M, et al. · N Engl J Med · 2006 · Trial result
    PubMed: PMID 16990388 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM, Holmes AJ, Lindeman N, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16983123 · NCT07361705 · Meningeal Carcinomatosis
  4. Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory.
    Armstrong TS, Cohen MZ, Eriksen L, et al. · Oncol Nurs Forum · 2006 · Trial result
    PubMed: PMID 15897941 · NCT07361705 · Meningeal Carcinomatosis

2005 (3 papers)

  1. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
    Omuro AM, Kris MG, Miller VA, et al. · Cancer · 2005 · Trial result
    PubMed: PMID 15844174 · NCT07361705 · Meningeal Carcinomatosis
  2. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.
    Ocean AJ, Vahdat LT · Support Care Cancer · 2005 · Trial result
    PubMed: PMID 15258838 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
    Pisters KM, Le Chevalier T · J Clin Oncol · 2005 · Background
    PubMed: PMID 15886314 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2003 (1 paper)

  1. Angiostatin prolongs the survival of mice with leptomeningeal metastases.
    Reijneveld JC, Taphoorn MJ, Kerckhaert OA, et al. · Eur J Clin Invest · 2003 · Background
    PubMed: PMID 12492456 · NCT04148898 (OWONBNSCLCLM) · Carcinoma, Non-Small-Cell Lung

2002 (2 papers)

  1. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN, Gritzapis AD, Tsitsilonis OE, et al. · Int J Cancer · 2002 · Trial result
    PubMed: PMID 11948464 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Neoplastic meningitis.
    Aparicio A, Chamberlain MC · Curr Neurol Neurosci Rep · 2002 · Trial result
    PubMed: PMID 11937001 · NCT07361705 · Meningeal Carcinomatosis

2001 (1 paper)

  1. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ, Fratesi P, Reese DM, et al. · J Clin Oncol · 2001 · Trial result
    PubMed: PMID 11099318 · NCT07271446 · Carcinoma, Non-Small-Cell Lung

1997 (2 papers)

  1. The emerging role of CTLA-4 as an immune attenuator.
    Thompson CB, Allison JP · Immunity · 1997 · Trial result
    PubMed: PMID 9354465 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
    Perez VL, Van Parijs L, Biuckians A, et al. · Immunity · 1997 · Trial result
    PubMed: PMID 9133420 · NCT07271446 · Carcinoma, Non-Small-Cell Lung

1995 (1 paper)

  1. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
    Waterhouse P, Penninger JM, Timms E, et al. · Science · 1995 · Trial result
    PubMed: PMID 7481803 · NCT07271446 · Carcinoma, Non-Small-Cell Lung

1990 (1 paper)

  1. Second cancers and other late side effects of cancer treatment. A review.
    Boivin JF · Cancer · 1990 · Trial result
    PubMed: PMID 2406000 · NCT07271446 · Carcinoma, Non-Small-Cell Lung

1987 (1 paper)

  1. The synaptonemal complexes of Caenorhabditis elegans: pachytene karyotype analysis of hermaphrodites from the recessive him-5 and him-7 mutants.
    Goldstein P · J Cell Sci · 1987 · Background
    PubMed: PMID 3793776 · NCT07486648 (Precision) · Carcinoma, Non-Small-Cell Lung

1984 (1 paper)

  1. Karnofsky performance status revisited: reliability, validity, and guidelines.
    Schag CC, Heinrich RL, Ganz PA, et al. · J Clin Oncol · 1984 · Trial result
    PubMed: PMID 6699671 · NCT07361705 · Meningeal Carcinomatosis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).